Autoantibodies against autonomic nervous tissues in Type 2 diabetes mellitus: No association with cardiac autonomic dysfunction

There is evidence that autoimmune factors contribute to the pathogenesis of cardiac autonomic dysfunction in Type 1 Diabetes mellitus (DM). To evaluat e the presence of autoantibodies against autonomic nervous tissues in Type 2 DM, 127 patients were studied for complement-fixing sympathetic and paras ympathetic ganglia (CF-SG and CF-PSG) autoantibodies with an indirect immun ofluorescence technique. Five cardiac reflex tests were performed to invest igate cardiac autonomic neuropathy. QTc interval was assessed in all patien ts. As a control group, 60 healthy non-diabetic subjects were also tested f or CF-SG and CF-PSG autoantibodies. CF-SG autoantibodies were detected in 11 (9%) and CF-PSG autoantibodies wer e observed in 7 (6%) Type 2 DM patients, whereas in control subjects, the f requency was 1 (2%) and 0 (0%) respectively (ns vs. Type 2 DM patients). In Type 2 DM patients with cardiac autonomic neuropathy (n=31, 24%), CF-SG au toantibodies and CF-PSG autoantibodies were detected in 3 (10%) patients, r espectively, compared to 8 (8%) and 4 (4%) in Type 2 DM patients without ca rdiac autonomic neuropathy (n=96, 76%, ns v. Type 2 DM with cardiac autonom ic neuropathy). Both CF-SG autoantibodies and CF-PSG autoantibodies were ob served in 2 (7%) Type 2 DM patients with cardiac autonomic neuropathy and 3 (3%) Type 2 DM patients without cardiac autonomic neuropathy. Type 2 DM pa tients with cardiac autonomic neuropathy demonstrated a longer QTc-interval (446+/-42ms) than Type 2 DM patients without cardiac autonomic neuropathy (413+/-45 ms, p= 0.0001). In Type 2 DM patients with a prolonged QTc-interv al (>440 ms: n=29, 23%), 2 (7%) patients presented with CF-SG and 3 (10%) h ad CF-PSG autoantibodies. In Type 2 DM, CF-SG and CF-PSG autoantibodies are not frequently observed. The results do not give evidence, that immunological factors - like in Type 1 DM - play a role in the pathogenesis of cardiac autonomic dysfunction in Type 2 DM.